Investigating the transmission of baloxavir‐resistant influenza viruses from treated index patients to untreated household contacts in the BLOCKSTONE study
Open Access
- 18 January 2023
- journal article
- research article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 17 (1) , e13079
Abstract
In a post‐hoc analysis of the phase 3 BLOCKSTONE study (JapicCTI‐184180), we investigated household transmission of baloxavir‐resistant (PA/I38X) influenza viruses. Using baloxavir resistance rates from prior clinical trials and the rate of influenza transmission observed in the study, the predicted number of PA/I38X transmission events was 4.8, assuming wild type and PA/I38X viruses were equally transmissible. However, no PA/I38X viruses were observed. These results suggest a low potential for baloxavir‐resistant influenza virus transmission from treated to untreated individuals, potentially due to reduced viral/transmission fitness for PA/I38X viruses and/or low viral titres at the time when resistant viruses arise.Keywords
Funding Information
- F. Hoffmann-La Roche
This publication has 7 references indexed in Scilit:
- Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret modelPLOS Pathogens, 2021
- Understanding the Impact of Resistance to Influenza AntiviralsClinical Microbiology Reviews, 2021
- Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trialThe Lancet Infectious Diseases, 2020
- Baloxavir Marboxil for Prophylaxis against Influenza in Household ContactsNew England Journal of Medicine, 2020
- Baloxavir Marboxil Single-dose Treatment in Influenza-infected ChildrenThe Pediatric Infectious Disease Journal, 2020
- In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunitAntiviral Research, 2018
- Baloxavir Marboxil for Uncomplicated Influenza in Adults and AdolescentsNew England Journal of Medicine, 2018